Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
01/23/20 4:34 AM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jan 12 2020
Summary ToggleAdverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook
- Jan 11 2020
Summary ToggleAdverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting
- Dec 18 2019
Summary ToggleAdverum Biotechnologies to Present at Upcoming Conferences
- Nov 20 2019
Summary ToggleAdverum Biotechnologies to Participate in Piper Jaffray’s 31st Annual Healthcare Conference